Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary AngioedemaBusiness Wire • 07/20/23
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical OperationsBusiness Wire • 07/17/23
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National SummitBusiness Wire • 07/14/23
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual MeetingBusiness Wire • 06/05/23
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate UpdateBusiness Wire • 05/11/23
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema WorkshopBusiness Wire • 04/28/23
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateBusiness Wire • 03/22/23
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22ndBusiness Wire • 03/08/23
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare ConferenceBusiness Wire • 03/06/23
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual MeetingBusiness Wire • 02/24/23
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual MeetingBusiness Wire • 02/21/23
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAEBusiness Wire • 02/08/23
Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?Zacks Investment Research • 12/27/22
What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/27/22
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 12/19/22
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockBusiness Wire • 12/15/22
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy SubjectsBusiness Wire • 12/15/22
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateBusiness Wire • 11/10/22
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual MeetingBusiness Wire • 11/07/22